Lymphangioma - Lenfanjyomhttps://en.wikipedia.org/wiki/Lymphangioma
Lenfanjyom (Lymphangioma) se malfòmasyon nan sistèm lenfatik ki karakterize pa blesi ki se spor mens. Malformasyon sa yo ka rive nenpòt laj epi yo ka enplike nenpòt pati nan kò a, men 90% rive nan timoun ki gen mwens pase 2 zan epi yo enplike tèt la ak kou. Lymphangiom akeri yo ka soti nan chòk, enflamasyon, oswa blokaj lenfatik. Depi yo pa gen okenn chans pou yo vin malfezan, lenfangiom yo anjeneral trete pou rezon kosmetik sèlman.

☆ Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
References Recent Progress in Lymphangioma 34976885 
NIH
Lymphangioma konnen tou kòm malformation lenfatik (LM) . Li se yon maladi vaskilè prezan depi nesans. Li karakterize pa kwasans nòmal nan tisi lenfatik anvan ak apre nesans. Lymphangioma afekte apeprè 1 nan 2000 a 4000 moun, san okenn diferans enpòtan ant sèks oswa ras. Pifò ka yo (80-90%) yo dyagnostike anvan laj de. Sentòm yo varye anpil, soti nan anfle lokalize rive nan gwo anomali nan chanèl lenfatik yo, pafwa mennen nan anfle grav ke yo rekonèt kòm elefantiasis. Pou egzanp, lymphangioma nan kou a ak nan figi ka lakòz anfle nan figi, ak nan ka grav, defigire. Lè li afekte lang lan, li ka mennen nan machwè twòp kwasans ak dan mal aliye. Nan bouch ak kou, li ka lakòz pwoblèm pou l respire ak ijans ki menase lavi yo. Nan je yo, li ka lakòz pèt vizyon, mouvman je limite, po je tonbe, ak je gonfle. Patisipasyon manm yo ka lakòz anfle ak kwasans nòmal nan tisi ak zo yo. Anjeneral, timè sa a ap grandi tou dousman, men enfeksyon, chanjman ormon, oswa blesi ka lakòz kwasans rapid, ki poze risk ki menase lavi ki mande tretman ijan.
Lymphangioma (lymphatic malformation, LM), a congenital vascular disease, is a low-flow vascular abnormality in lymphatic diseases that is characterized by excessive growth of lymphatic tissue during prenatal and postpartum development. The incidence rate of LM is ~1:2000–4000, with no variation between genders and races. Most patients (80–90%) are diagnosed before the age of two. The clinical manifestations of lymphangioma are quite different among patients, varying from local swelling leading to superficial mass to a large area of diffuse infiltrating lymphatic channel abnormalities resulting in elephantiasis. Cervicofacial LM can cause facial elephantiasis, and in some severe cases, it can lead to serious disfigurement of the face. Tongue LM can lead to mandibular overgrowth and occlusal asymmetry, and oral and cervical LM can cause obstructive acute respiratory distress and life-threatening situations. Orbital LM may lead to decreased vision, decreased extraocular muscle movement, ptosis and exophthalmos. LM of the extremities can trigger swelling or gigantism, accompanied by overgrowth of soft tissue and bones. LM usually grows slowly and steadily, but under certain conditions, such as infection, hormonal changes or trauma, it can grow explosively and become a life-threatening disease requiring immediate treatment.
 Lymphangioma: Is intralesional bleomycin sclerotherapy effective? 22279495 
NIH
Nan etid retrospektiv sa a, nou te revize 24 timoun ki te gen lymphangioma epi yo te trete ak piki solisyon bleomicin soti janvye 1999 rive desanm 2004. Pifò nan blesi yo (63%) te disparèt nèt, 21% te resevwa yon bon repons, ak 16% pa t byen reponn. De pasyan te gen timè a tounen pita, ak de lòt te gen absè kote yo te resevwa piki yo. Erezman, nou pa t wè okenn lòt gwo pwoblèm oswa efè segondè.
This is a retrospective study of 24 children diagnosed with lymphangioma and treated with intralesional injection of bleomycin aqueous solution from January 1999 to December 2004. Complete resolution was seen in 63% (15/24) of lesions, 21% (5/24) had good response and 16% (4/24) had poor response. The tumour recurred in 2 patients. Two other patients had abscess formation at the site of injection. No other serious complications or side effects were observed.
 Surgical Resection of Acquired Vulvar Lymphangioma Circumscriptum - Case reports 24665431 
NIH
Kalite prensipal yo nan lymphangioma yo jan sa a - lymphangioma circumscriptum, cavernous lymphangioma, cystic hygroma, lymphangioendothelioma. Sa yo fè alantou 26% nan timè vaskilè benign nan timoun men yo mwens komen nan granmoun. Lymphangioma circumscriptum , kalite ki pi souvan, montre kanal lenfatik ki soti nan po a, ki fòme vesik klè ki ranpli ak likid ki sanble ak anjandre krapo, ansanm ak anfle tisi yo. Li tipikman parèt sou zòn ki gen yon rezo lenfatik rich tankou branch yo, kòf, ak anbabra. Yon fanm 71-zan te vin nan klinik nou an ak anfle nan janm ki pèsistan, boul woz sou jenital li, demanjezon, ak koule likid lenfatik. Nou te retire chirijikal tout boul yo ak yon pwosedi ki rele bilateral gwo labiectomy, kanpe nan nivo fascia Colles, pandan y ap prezève klitoris la ak fourchette.
The predominant types of lymphangioma are lymphangioma circumscriptum (LC), cavernous lymphangioma, cystic hygroma, and lymphangioendothelioma. These entities account for approximately 26% of benign vascular tumors in children but are rarer in adults. LC is the most common form of cutaneous lymphangioma and is characterized by superficial lymphatic ducts protruding through the epidermis. This condition results in clusters of clear fluid-filled vesicles resembling frog spawn and associated tissue edema. It is usually found on the proximal extremity, trunk, and axilla, which has an abundant lymphatic system. A 71-year-old female presented to our outpatient clinic with persistent edema of both lower limbs, clusters of pink labial papules, pruritus, and watery lymph oozing. We removed all the papules by performing bilateral major labiectomy down to the level of Colles' fascia, sparing the clitoris and fourchette.